In a report released today, Edward White from H.C. Wainwright reiterated a Buy rating on Inhibikase Therapeutics (IKT – Research Report), with a price target of $5.00. The company’s shares opened today at $0.62.
White covers the Healthcare sector, focusing on stocks such as SAB Biotherapeutics, TG Therapeutics, and InflaRx. According to TipRanks, White has an average return of -10.8% and a 32.06% success rate on recommended stocks.
Currently, the analyst consensus on Inhibikase Therapeutics is a Moderate Buy with an average price target of $5.00.
See Insiders’ Hot Stocks on TipRanks >>
Based on Inhibikase Therapeutics’ latest earnings release for the quarter ending March 31, the company reported a quarterly revenue of $64.52 thousand and a GAAP net loss of $4.48 million. In comparison, last year the company earned a revenue of $46.03 thousand and had a GAAP net loss of $4.64 million
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Inhibikase Therapeutics Inc is a clinical stage pharmaceutical company developing therapeutics for Parkinson’s Diseases and related disorders inside and outside the brain. Its pipeline product, IkT-148009, targets underlying disease mechanisms to reverse the course of Parkinson’s disease and the GI complications of Parkinson’s disease.
Read More on IKT:
